Le Lézard
Classified in: Health
Subjects: PER, WOM

FEMSELECT APPOINTS CHIEF MEDICAL OFFICER


Dr. Karla Loken to Bolster US Leadership Team

NEWARK, Del., Feb. 1, 2023 /PRNewswire/ -- FEMSelect Ltd., developer of EnPlace®, a minimally invasive, meshless approach to pelvic organ prolapse procedures announced today the appointment of Karla Loken, DO, FACOOG as its US-based Chief Medical Officer. Dr. Karla Loken joins FEMSelect's executive team at a pivotal time of US expansion and is tasked with helping the company meet its objectives for 2023 and beyond.

Dr. Loken is a board-certified OBGYN with over 20 years of post-graduate experience in women's health. She transitioned to industry where she gained valuable experience in Pharmacovigilance (medical and device safety), Medical Affairs, and Clinical Development; and has worked with pharma, device, and diagnostic companies as well as consulting for several FemTech startups.

Co-CEO Deborah Garner commented: "Dr. Loken's passionate advocacy and decades of experience across multiple surgical devices and disease states will help us further commercialize EnPlace® for women suffering from pelvic floor stability concerns. We are excited to have her join us at this critical juncture of outreach."

Loken responded: "I am honored to be joining Co-CEOs Debbie Garner and Renee Selman and the entire FEMSelect team. I share their focus on equity and inclusion in research and on increasing awareness and funding for women's health. And, I am eager to help them meet the unmet demand by women who need innovative solutions for pelvic organ prolapse and other conditions."

Pelvic Organ Prolapse (POP) occurs when the muscles and tissues supporting the pelvic organs (the uterus, bladder, or rectum) become weak and drop out of the vagina. Many women are embarrassed to talk to a doctor about the symptoms. More than 3 million US women suffer from POP and surgical options are complicated and invasive. EnPlace®, cleared by the FDA for pelvic floor fixation, enables a minimally invasive approach in under 30 minutes and clinical studies have shown women can return to normal activities within just a few days.

About FEMSelect

FEMSelect is a women-led company with a mission to make a lasting impact on women's health by delivering innovative technologies that provide consistent results in a patient-centric manner and dramatically improve outcomes for women.

For more information about the EnPlace® system, please contact [email protected] or visit https://femselect.com.

SOURCE FEMSelect


These press releases may also interest you

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...

at 11:00
Eagle Hill Consulting has earned another top workplace award, this time selected by The Washington Business Journal as a 2024 Best Places to Work in the extra-large sized company category. Eagle Hill also has earned multiple best workplace awards...

at 11:00
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura,...

at 10:53
A one-of-a-kind healthcare collaborative, the Center for Better Aging (CBA) located at St. Bernard Hospital, opens in July with a health equity mandate to serve the growing 50+ population on Chicago's Greater South Side. ...



News published on and distributed by: